Astrazeneca Set To Buy Cincor For $1.8bn

Sales & Marketing

AstraZeneca set to buy CinCor for $1.8bn

AstraZeneca has announced that it is set to acquire the clinical-stage biopharmaceutical company CinCor in a deal worth up to $1.8bn.

US-based CinCor focuses on the development of novel treatments for resistant and uncontrolled hypertension, as well as to treat chronic kidney disease.

The deal is intended to improve AstraZeneca’s cardiorenal pipeline through the acquisition of CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) that lowers blood pressure in treatment-resistant hypertension.

The company hopes that baxdrostat will be its leading next-generation ASI due to the fact that it is highly selective for aldosterone synthase and tends to spare the cortisol pathway in human patients. It can also be used in combination with Farxiga, which “complements

AstraZeneca’s strategy to provide added benefit across cardiorenal diseases, where there is a high unmet medical need.”

Mene Pangalos, executive vice president of biopharmaceutical research and development at AstraZeneca, commented: “Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat.”

He continued: “Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease, and being able to effectively reduce this would offer a much-needed treatment option for these patients.”

Treatment programme for CVD to be developed as part of partnership between Novartis and Ionis

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and licence agreement with Novartis, aiming to discover, develop and commercialise a novel medicine for patients with lipoprotein(a) or lp(a)-driven cardiovascular disease (CVD).

Biogen plans to acquire Reata Pharmaceuticals for $7.3bn

Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for approximately $7.3bn, or $172.50 per share.

Rare disease treatments to be researched in partnership between Pfizer and AstraZeneca’s Alexion

Alexion has announced that it has entered a definitive purchase and licence agreement with Pfizer.

Eli Lilly shares plans to acquire Versanis Bio for $1.9bn

Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focusing on the development of new medicines to treat cardiometabolic diseases.

LaNova Medicines and AstraZeneca sign global exclusive licence agreement for preclinical ADC

Chinese biotechnology company LaNova medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive licence agreement for a preclinical stage antibody drug conjugate (ADC).

Treatment programme for CVD to be developed as part of partnership between Novartis and Ionis

Biogen plans to acquire Reata Pharmaceuticals for $7.3bn

Rare disease treatments to be researched in partnership between Pfizer and AstraZeneca’s Alexion

Eli Lilly shares plans to acquire Versanis Bio for $1.9bn

LaNova Medicines and AstraZeneca sign global exclusive licence agreement for preclinical ADC

Pharmafocus

Categories

Social Footprints